Krystal Biotech Stock (NASDAQ:KRYS), Trade Ideas

Krystal Biotech

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Biotech

News

Markets

Trading Ideas

General

KRYS

While &#34;the trend is your friend&#34; when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn&#39;t easy.

Krystal Biotech is on the Move, Here&#39;s Why the Trend Could be Sustainable

Penny Stocks

Small Cap

Intraday Update

Movers

APGE

AVAV

DAVE

NYCB

REAL

RSKD

SRRK

SYRE

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.

NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday

Earnings

Price Target

Analyst Ratings

Krystal Biotech, Inc.  (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday.

Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results

Krystal Biotech Inc

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly set to lay off 693 employees at its Nevada facilities as part of the <a href="https://www.benzinga.com/news/24/04/38244436/breaking-tesla-said-to-be-laying-off-over-14-000-employees">10% layoff</a> announced by the company earlier this month to reduce costs amid falling EV sales and margins. 
What Happened: Tesla has filed a notice with the Nevada Department of Employment, Training, and Rehabilitation, indicating its intention to lay off 693 employees at its Sparks, Nevada facilities, Reuters reported.
Tesla did not immediately respond to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga's</a> request for comment. 
Tesla announced its plan to lay off about 14,000 employees, or 10% of its global workforce, on April 15. 
"About every five years, we need to reorganize and streamline the company for the next phase of growth," company CEO&nbsp;Elon Musk&nbsp;said on X&nbsp;<a href="https://www.benzinga.com/news/24/04/38263933/elon-musk-re-enters-wartime-ceo-mode-tesla-chief-explains-necessity-of-massive-job-cuts-amid-report" target="_blank" rel="noreferrer noopener">about the sweeping job cuts</a>.
Mapping The Layoffs Worldwide: According to WARN notices filed with the states of Texas and California, Tesla will eliminate 3,332 jobs in California and 2,688 positions in Texas, <a href="https://www.benzinga.com/news/24/04/38452751/teslas-biggest-layoffs-mapped-where-has-ev-giant-cut-most-jobs">totaling over 6,000 positions, </a>starting June 14.
The company also intends to cut around 400 jobs in Germany and 285 employees in Buffalo, New York, starting July 15.
Tesla&#8217;s Disappointing Results: Tesla's layoffs reflect the broader challenges facing the company, including declining sales and pricing pressures. For the first quarter, the EV giant reported revenue of $21.3 billion, down from the $23.33 billion reported a year earlier. This is the first time the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38398667/tesla-bulls-praise-musks-q1-earnings-call-see-ev-giant-on-collision-course-with-ube">company&#8217;s quarterly revenue has fallen</a> since the pandemic in 2020. 
Tesla's net profit stood at $1.13 billion, falling 55% from $2.51 billion a year earlier. 
CEO&nbsp;Elon Musk, however, managed to&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38402856/tesla-bull-says-elon-musk-delivered-rip-the-band-aid-off-q1-but-cautions-this-could" target="_blank" rel="noreferrer noopener">assuage some investor concerns</a> by promising a faster rollout of cheaper EV models. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:&nbsp;<a href="https://www.benzinga.com/news/24/04/38474811/check-your-inbox-tesla-sends-out-expedited-cybertruck-delivery-invites-to-long-term-shareholders">&#8216;Check Your Inbox!&#8217;: Tesla Sends Out Expedited Cybertruck Delivery Invites To Long-Term Shareholders</a>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy of Tesla.

Tech

TSLA

Tesla To Cut 693 Jobs In Nevada Amid Global Workforce Reduction: Government Notice

Elon Musk announced the suspension of ad revenue sharing for certain creators on his social media platform, X, formerly Twitter, <a href="https://www.benzinga.com/news/23/10/35153897/elon-musks-plans-to-weed-out-bots-from-x-enables-verified-user-only-replies-option-what-it-means">due to bot spamming</a>.
What Happened: Musk took to X to reveal that the ad revenue sharing for some creators will be paused. This decision comes as a response to an ongoing investigation into the bot problem on his social media platform.
"Ad revenue sharing will be paused for some creators pending investigation into use of bots to spam likes, replies, DMs, etc."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ad revenue sharing will be paused for some creators pending investigation into use of bots to spam likes, replies, DMs, etc
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1783945045529518219?ref_src=twsrc%5Etfw">April 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The billionaire entrepreneur emphasized the purpose of creator payouts. However, he noted that some users are exploiting the system to generate ad revenue, which is &#8220;obviously not ok.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/04/38264187/elon-musk-says-charging-new-x-users-a-small-fee-is-the-only-way-to-curb-bot-onslaught">Elon Musk Says Charging New X Users A &#8216;Small Fee&#8217; Is The Only Way To Curb Bot Onslaught</a>
"The point of creator payouts is to incentivize high-quality content on X. In some cases, we are seeing the opposite, where people are spamming the system to generate ad money."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The point of creator payouts is to incentivize high quality content on &#120143;. In some cases, we are seeing the opposite, where people are spamming the system to generate ad money. That is obviously not ok.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1783954236671512767?ref_src=twsrc%5Etfw">April 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Musk&#8217;s decision to halt ad revenue sharing for certain creators is the latest in a series of moves aimed at addressing the bot problem on X.
Earlier this month, Musk <a href="https://www.benzinga.com/news/24/04/38264187/elon-musk-says-charging-new-x-users-a-small-fee-is-the-only-way-to-curb-bot-onslaught">announced</a> that the platform would charge a small fee for new users to post, with the primary goal of curbing the bot onslaught.
This is not the first time Musk has taken steps to combat bot activity on X. In October, the platform began <a href="https://www.benzinga.com/news/23/10/35300682/just-joining-elon-musks-x-you-will-now-have-to-shell-out-1-for-proper-access-if-you-live-in-these-tw">charging a $1 annual subscription fee</a> for new users in New Zealand and the Philippines as part of its &#8220;Not A Bot&#8221; program, aimed at mitigating spam, manipulation, and bot activity on the platform.
Check out more of Benzinga's Future Of Consumer Tech by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next: <a href="https://www.benzinga.com/news/24/04/38460718/elon-musk-weighs-in-after-x-user-says-banning-tiktok-sets-a-precedent-that-government-can-ban-any-ap">Elon Musk Weighs In After X User Says &#8216;Banning TikTok Sets A Precedent That Government Can Ban Any App&#8230;&#8217;</a>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Social Media

Elon Musk Says Ad Revenue Sharing Will Be 'Paused' For Some X Creators Over Pending Investigation Into 'Use Of Bots To Spam Likes, Replies'

The U.S. and China have agreed to hold their first high-level talks on artificial intelligence (AI). This was confirmed by U.S. Secretary of State Antony Blinken during a press conference in Beijing on Friday. The two nations will discuss potential <a href="https://www.benzinga.com/news/24/04/38310022/former-openai-researcher-who-predicted-theres-a-50-chance-ai-could-kill-us-all-is-now-heading-us-ai">risks and safety concerns</a> associated with AI.
What Happened: The upcoming U.S.-China intergovernmental dialogue on AI was announced by Blinken during his discussions with Chinese officials in Beijing. The talks are scheduled to take place in the &#8220;coming weeks,&#8221; <a href="https://www.cnbc.com/2024/04/26/us-china-to-hold-first-ai-talks-tiktok-stalemate-ongoing.html">reported</a> CNBC.
While the <a href="https://www.benzinga.com/news/24/04/38460718/elon-musk-weighs-in-after-x-user-says-banning-tiktok-sets-a-precedent-that-government-can-ban-any-ap">future of TikTok</a>, owned by Chinese internet technology company ByteDance Ltd., remains uncertain due to U.S. restrictions, Blinken mentioned that the topic "did not come up&#8221; during the talks.
China&#8217;s foreign ministry confirmed the AI talks and outlined a broader five-point agreement between the two nations. This includes efforts to stabilize and develop U.S.-China relations, expand cultural exchanges, and continue consultations on international and regional issues.
See Also: <a href="https://www.benzinga.com/news/24/04/38400945/metas-massive-1b-bet-on-nvidia-h100-gpu-cluster-will-dwarf-every-other-companys-target-but-zuckerber?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Meta&#8217;s Massive $1B Bet On Nvidia H100 GPU Cluster Will Dwarf Every Other Company&#8217;s Target, But Zuckerberg</a>
Amid ongoing trade and national security concerns, the U.S. and its allies have accused Chinese companies of flooding international markets with low-cost goods, particularly green technologies such as electric vehicles. Beijing has denied these allegations.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The U.S. and China&#8217;s rivalry in AI has been a topic of much discussion. Both countries have made <a href="https://www.benzinga.com/news/24/03/37843540/why-intel-shares-are-rallying-nearly-4-premarket-today">significant investments in AI</a>, with the pace of innovation being a particular concern for China.
The upcoming AI talks could provide insight into the future of this technological competition, as well as the potential for cooperation in this area.
U.S. has currently <a href="https://www.benzinga.com/government/24/04/38140039/us-embargo-on-nvidia-stings-hard-chinas-ai-development-lags-peers-alibabas-joe-tsai-reveals">imposed restrictions</a> on the export of advanced AI chips to China, impacting companies like Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), among others.
Despite these tensions, China has managed to <a href="https://www.benzinga.com/markets/equities/24/04/38459947/as-us-tightens-screws-on-nvidia-intel-chip-exports-to-china-huaweis-latest-phone-uses-made-in-ch">develop its own chipsets</a>. The upcoming AI talks could shed light on the future of this competition and the potential for cooperation in this critical area of technology.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38453639/another-picasso-like-performance-top-tech-analyst-praises-satya-nadella-says-micros" target="_blank" rel="noreferrer noopener">‘Another Picasso-Like Performance:' Top Tech Analyst Praises Satya Nadella, Says Microsoft Is Top ‘AI Draft Pick' With 20% Rally In Store</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

Global

NVDA

US, China Set To Hold First High-Level Talks On AI, Blinken Confirms: Tiktok 'Did Not Come Up' In Discussion

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has started sending <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36039263/did-tesla-overpromise-and-underdeliver-with-the-cybertruck">Cybertruck delivery invites</a> to long-term shareholders who opted for early delivery, company executive Martin Viecha said on Friday. 
What Happened: &#8220;The first batch of early Cybertruck delivery invites for long-term shareholders just went out &#8211; please check your inbox!,&#8221; Viecha wrote in a post on X, formerly Twitter. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The first batch of early Cybertruck delivery invites for long-term shareholders just went out &#8211; please check your inbox! Sorry about the delay, verifying statements of so many shareholders is taking some time. More to come! Thanks <a href="https://twitter.com/J0se?ref_src=twsrc%5Etfw">@J0se</a>, his team and the IR team &#x1f642; <a href="https://t.co/jshOaWmm6u">https://t.co/jshOaWmm6u</a>
&mdash; Martin Viecha (@MartinViecha) <a href="https://twitter.com/MartinViecha/status/1784006816625770877?ref_src=twsrc%5Etfw">April 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tesla announced an <a href="https://www.benzinga.com/news/24/03/37610567/tesla-offers-early-cybertruck-delivery-to-long-term-shareholders-how-to-check-if-you-qualify">exclusive offer to its long-term shareholders</a>, allowing them to receive early delivery of the Foundation Series Cybertruck, in March. The criteria was that the Cybertruck reservation be made in the shareholder&#8217;s name before March 1. Each participant must further provide brokerage statements showing that they owned Tesla shares on Feb. 28, 2021, and owned at least 500 Tesla shares on Feb. 29. The more recent brokerage statement must also show that the participant still owns at least half of the shares they owned as of Feb. 28, 2021, the company said. 
Viecha on Friday pegged the delay in sending out the first batch of invites to the statement verification process. The company had to verify statements from &#8220;so many shareholders,&#8221; he said, hinting that several shareholders opted into the offer. 
Cybertruck Delivery Timeline: Tesla aims to deliver 250,000 units of the Cybertruck in a year <a href="https://www.benzinga.com/news/23/10/35322048/tesla-ceo-elon-musk-details-enormous-challenges-in-reaching-volume-production-for-cybertruck-we-dug">starting in 2025. </a>
During Tesla's third-quarter earnings call in October, a month before the Cybertruck&#8217;s delivery event,&nbsp;Musk had said that over a million people had already reserved the vehicle. 
In January, Tesla Supply Chain Vice President&nbsp;Karn Budhiraj&nbsp;said&nbsp;that the conversion of reservations to orders for the vehicle has been &#8220;very encouraging&#8221; and that the company has been receiving new orders since the vehicle's launch, implying that those lower below the waitlist might have to wait for their vehicles until 2026 or later<a href="https://www.benzinga.com/news/24/02/37174949/want-your-cybertruck-delivered-faster-tesla-offers-priority-option-if-you-have-these-many-referral-c"> without these offers.</a> 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More: <a href="https://www.benzinga.com/government/24/04/38454591/breaking-nhtsa-starts-probe-into-teslas-software-fix-for-2m-vehicles-recalled-in-december">Did Tesla&#8217;s Software Update Fix Autosteer Problems For 2M Cars? NHTSA Starts Probing</a>
Photo via Shutterstock

'Check Your Inbox!': Tesla Sends Out Expedited Cybertruck Delivery Invites To Long-Term Shareholders

Jim Cramer, the host of CNBC&#8217;s &#8220;Mad Money,&#8221; has outlined the key events that investors should keep an eye on in the upcoming week.
What Happened: Cramer highlighted the significant events scheduled for the week, including earnings reports from&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and&nbsp;Eli Lilly and Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>),&nbsp;<a href="https://www.cnbc.com/2024/04/26/cramers-week-ahead-fed-meeting-and-apple-amazon-eli-lilly-report.html">reported</a> CNBC on Friday.
He also spoke about the importance of the <a href="https://www.benzinga.com/topic/fomc-meeting">Federal Reserve meeting</a> on Wednesday and the&nbsp;employment figures from the Department&nbsp;of Labor on Friday.
The Mad Money host expressed his concerns about the economy, stating, &#8220;We&nbsp;have to run such a&nbsp;ridiculous gauntlet next week that&nbsp;I have no idea how&nbsp;it'll play out.&#8221; Adding, &#8220;But&nbsp;I do think the economy's&nbsp;getting weaker — I just&nbsp;hope the Federal Reserve has noticed.&#8221;
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
On Monday,&nbsp;SoFi&nbsp;and&nbsp;Domino&#8217;s Pizza&nbsp;will report their earnings. Tuesday will see reports from&nbsp;Eli Lilly,&nbsp;McDonald&#8217;s,&nbsp;Amazon, and&nbsp;Starbucks. Wednesday will feature reports from&nbsp;CVS,&nbsp;Pfizer,&nbsp;Wingstop,&nbsp;Carvana, and&nbsp;Marriott, as well as the Fed&#8217;s rate announcement.
Cramer said Eli Lilly&#8217;s outcomes will offer clarity on the sales performance of the <a href="https://www.benzinga.com/general/biotech/24/04/38356901/changing-frugal-eating-habits-how-novo-nordiskeli-lillys-weight-loss-drugs-reshaping-food-spendin">company&#8217;s weight loss</a> and diabetes drug, along with further details on the potential approval timeline for its Alzheimer&#8217;s treatment by <a href="https://www.benzinga.com/general/biotech/24/03/37558545/eli-lillys-donanemab-for-alzheimers-hits-fda-speed-breaker-biogen-stock-gains-on-delayed-decision">the Food and Drug Administration</a>.
On Thursday, Apple is set to release its report, with Cramer highlighting <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38378204/apple-is-a-top-stock-pick-for-2024-analyst-says-4-catalysts-to-look-for-in-next-ear">significant investor skepticism</a> toward the Big Tech firm. He pointed out that <a href="https://www.benzinga.com/news/24/03/37821802/apple-vision-pro-gets-nvidia-boost-with-dedicated-data-centers-to-stream-advanced-3d-experiences">Apple&#8217;s collaboration</a> with Nvidia, facilitating enterprise applications for the Vision Pro, could potentially bolster the stock.
Why It Matters: On Thursday, Cramer <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38456821/jim-cramer-scoffs-at-disproportionate-coverage-of-apple-while-google-and-microsoft-">criticized the disproportionate coverage</a> of Apple&#8217;s struggles compared to the successes of Google and Microsoft. He pointed out that while Apple&#8217;s challenges with antitrust regulations and declining iPhone sales in China received major attention, the <a href="https://www.benzinga.com/news/24/04/38459818/real-deal-amid-microsoft-google-earnings-techpreneur-says-by-2030-companies-not-fully-utilizing-ai-w">remarkable quarterly results</a> of Google and Microsoft barely made the news.
He has previously also&nbsp;<a href="https://www.benzinga.com/news/earnings/24/04/38406798/jim-cramer-takes-potshots-at-tesla-boeing-shrugs-off-post-earnings-rally-as-smacks-of-fiction-horre">expressed skepticism</a>&nbsp;about the post-earnings rally of Tesla and Boeing, stating that it &#8220;smacks of fiction not fact.&#8221; 
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/markets/equities/24/04/38368953/jim-cramer-sees-nvidia-as-going-from-star-of-the-show-to-being-the-goat-of-the-game?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Sees Nvidia As Going &#8216;From Star Of The Show To Being The Goat Of The Game&#8217;</a>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo: Courtesy of Scott Beale on Flickr

Market Summary

AAPL

AMZN

Jim Cramer Weighs In Ahead Of Apple, Amazon, Eli Lilly Earnings: 'We Have To Run Such A Ridiculous Gauntlet Next Week'

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has hiked the price of its new <a href="https://www.benzinga.com/news/24/04/38401202/teslas-new-53k-model-3-performance-eligible-for-full-tax-credits-but-leasing-long-range-might-be-che">Model 3 Performance </a>in the U.S. by $1000, merely days after its launch. 
What Happened: The Model 3 Performance is now priced at $53,990 on Tesla&#8217;s website. The company launched the new variant only on Tuesday, ahead of its first-quarter results. 
The Model 3 Performance, unlike the other two versions of Model 3, is eligible for a $7,500 federal EV tax credit, taking the effective price for eligible buyers down to $46,490, below even the Long Range version of the vehicle. 
The Performance version has a range of 296 miles and a top speed of 163 mph. On ordering the vehicle now, customers can take delivery by June. 
Why It Matters: In January, Tesla introduced the <a href="https://www.benzinga.com/news/24/01/36570546/you-can-finally-order-teslas-new-model-3-in-america-heres-its-starting-price">updated Model 3</a> in the U.S., initially offering two variants: rear-wheel drive and long-range. The Performance variant was conspicuously absent from the listings. However, a company executive affirmed its forthcoming availability.
Tesla slashed prices on all trim levels of the Model Y, S, and X in the U.S. by <a href="https://www.benzinga.com/markets/equities/24/04/38345362/tesla-slashes-model-s-x-and-y-prices-in-us-by-2-000-in-late-friday-move-as-volume-growth-turns-n">$2,000 earlier this month. </a>It spared the refreshed Model 3 then. 
Price Action:&nbsp;Tesla stock closed down 1.11% at $168.28 per share on Friday, according to data from&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro.</a>&nbsp;The stock is down 32.26% year-to-date.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/mobility" rel="noreferrer noopener">following this link</a>.
Read More:<a href="https://www.benzinga.com/news/24/04/38453221/another-blow-to-tesla-hertzs-ev-disposal-plan-jumps-by-10k-as-car-rental-company-aims-for-95-gas-pow"> Another Blow To Tesla? Hertz&#8217;s EV Disposal Plan Jumps By 10K As Car-Rental Company Aims For 95% Gas-Powered Fleet By Year-End</a>
Photo via Shutterstock

Tesla Increases Price Of Model 3 Performance By $1K In US Days After Launch

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has reportedly resumed discussions with Microsoft Corp.-backed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) OpenAI about incorporating the startup&#8217;s AI technology into the <a href="https://www.benzinga.com/news/24/03/37932418/apple-reportedly-readying-ios-18-with-home-screen-redesign-and-ai-upgrades">upcoming iPhone features</a>.
What Happened: Apple is in talks with OpenAI to potentially integrate its technology into the iPhone&#8217;s next operating system, iOS 18, <a href="https://www.bloomberg.com/news/articles/2024-04-26/apple-intensifies-talks-with-openai-for-iphone-generative-ai-features">Bloomberg</a> reported.
The companies are discussing the terms of the agreement and how OpenAI&#8217;s features would be integrated into iOS 18.
This development marks the reopening of discussions between the two companies. While Apple had initially collaborated with OpenAI earlier this year, there has been minimal engagement between the two entities since then.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Apple has not yet made a final decision on its partners and there is no guarantee that a deal will be reached. The company may ultimately strike a deal with both OpenAI and Google or choose another provider altogether.
Apple and OpenAI did not immediately respond to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga's</a> request for comment.
See Also: <a href="https://www.benzinga.com/news/24/04/38424000/mark-zuckerberg-shades-apple-vision-pro-once-again-calls-it-fashionable-ai-glasses-without-a-display?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Shades Apple Vision Pro Once Again, Calls It &#8216;Fashionable AI Glasses Without A Display&#8217;</a>
The iOS 18 update is set to include several new features based on <a href="https://www.benzinga.com/markets/equities/24/03/37819063/apples-in-house-ai-features-for-ios-18-are-codenamed-project-graymatter-separate-from-googles-ge">Apple&#8217;s in-house large language model AI model</a>. The company is also seeking partners to power a chatbot-like feature similar to OpenAI&#8217;s ChatGPT.
Why It Matters: The renewed talks between Apple and OpenAI come amidst Apple&#8217;s <a href="https://www.benzinga.com/news/24/03/37771653/apple-in-talks-with-google-to-license-gemini-ai-models-for-future-iphones-report">ongoing discussions with</a> Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google about licensing the latter&#8217;s Gemini AI models for future iPhones. The potential deal with OpenAI and Google could also significantly impact the iPhone&#8217;s AI capabilities.
Apple&#8217;s CEO, Tim Cook, has been vocal about the company&#8217;s plans to <a href="https://www.benzinga.com/markets/equities/24/03/37871211/google-or-microsoft-backed-openai-apple-hasnt-picked-the-winner-yet-for-its-ai-ambitions-report">introduce new AI features</a> on a &#8220;very thoughtful basis.&#8221; By collaborating with external partners like OpenAI and Google, Apple aims to accelerate its AI push and enhance its devices&#8217; AI capabilities while mitigating potential risks.
Price Action: Apple's shares closed 0.35% lower at $169.30 on Friday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37784585/gene-munster-says-apple-will-fight-to-rebrand-gemini-on-iphone-but-the-deal-is-what" target="_blank" rel="noreferrer noopener">Gene Munster Says ‘Apple Will Fight' To Rebrand Gemini On iPhone, But The Deal Is What Google Investors Have Been ‘Waiting For The Last 6 Months'</a>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Thai Nguyen on Unsplash

GOOG

GOOGL

MSFT

Goodbye Google Gemini? Apple In Talks With Microsoft-Backed OpenAI For iPhone AI Features: Report

Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO&nbsp;Elon Musk&nbsp;has placed high hopes on its&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/03/38012152/tesla-rolls-out-30-day-free-trial-for-its-full-self-driving-software" rel="noreferrer noopener">Full Self-Driving</a>&nbsp;(FSD) software. However, the electric vehicle giant&#8217;s autonomous driving technology continues to be controversial. On Thursday, a tech entrepreneur made some shocking claims that further clouded the outlook for the technology.
Red Flags: <a href="https://www.benzinga.com/23/11/35841525/elon-musk-under-fire-facebook-co-founder-calls-for-resignation-from-tesla-amid-antisemitism-controve">Dustin Moskovitz</a>, co-founder of&nbsp;Facebook&nbsp;(now&nbsp;Meta), expressed strong concerns about Tesla in a post on Meta&#8217;s&nbsp;Threads&nbsp;messaging app. He compared Tesla&#8217;s situation to the infamous collapse of energy company&nbsp;Enron, stating, &#8220;I know I sound crazy to most people who don&#8217;t follow $TSLA closely but at this&nbsp;point&nbsp;it&nbsp;really&nbsp;needs to be said. This is Enron now, folks.&#8221;
Enron executives systematically inflated their company&#8217;s financial performance for years, hiding billions in debt through a web of complex financial instruments. It eventually came crashing down, leading to one of the biggest corporate scandals in U.S. history.
Moskovitz, who also serves as CEO of work-management platform&nbsp;Asana, suggested that Tesla could face legal repercussions. &#8220;People are going to jail at the end,&#8221; he warned.
See Also:&nbsp;<a target="_blank" href="https://www.benzinga.com/money/everything-you-need-to-know-about-tesla-stock" rel="noreferrer noopener">Everything You Need To Know About Tesla Stock</a>
Skeletons In The Closet?&nbsp;Moskovitz accused Tesla of presenting misleading data about FSD capabilities. &#8220;The data doesn&#8217;t say what they claim it says, even when they make it up,&#8221; he stated. He further alleged that Tesla has &#8220;committed consumer fraud on a massive scale&#8221; through misrepresentations about FSD, vehicle ranges, and potentially even odometer readings.
There have been social media reports of Tesla vehicles displaying inaccurate odometer readings, potentially affecting range calculations. Moskovitz shared a social media post from a user who claimed a 20% discrepancy between their Tesla Model Y&#8217;s odometer and a&nbsp;Lexus RZ.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Is Tesla inflating odometer to show more range, ding lessors with over miles and duck repairs under warranty? As I return my leased Model Y I noticed the odometer is off by 20% vs my Lexus RZ. Turns out other Tesla owners have a similar concern. Is Musk gaming the Tesla odometer? <a href="https://t.co/jM8Pmf6U1D">https://t.co/jM8Pmf6U1D</a> <a href="https://t.co/h4BB0iiar6">pic.twitter.com/h4BB0iiar6</a>
&mdash; Facts Chaser &#x1f30e; &#x1f926;&#x1f3fb;&#x200d;&#x2642;&#xfe0f; (@Factschaser) <a href="https://twitter.com/Factschaser/status/1782247551896269052?ref_src=twsrc%5Etfw">April 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tesla, however, has not responded to any of these allegations.
Questionable FSD Progress:&nbsp;To support his claims of fraudulent data, Moskovitz shared a Bloomberg chart on Tesla&#8217;s software sales revenue. &#8220;Tesla makes up more in revenue straight from their imagination every single quarter than my company does selling actual products in a year,&#8221; he quipped.
Moskovitz also questioned the recent update to Tesla&#8217;s FSD progress graph. He pointed out that Tesla AI celebrated achieving 1 billion FSD miles on April 3, shortly after <a href="https://www.benzinga.com/news/24/03/37926548/elon-musk-rolls-out-free-full-self-driving-trial-to-us-tesla-owners-but-only-for-a-month">the free FSD trial</a> began on March 25.&nbsp;
&#8220;The new graph is humorously ambiguous&nbsp;wrt&nbsp;dates. Is &#8216;March 2024&#8217; the 1st? The 31st? Why is the inflection &#x2A;after&#x2A; the 1B miles milestone in the new graph?&#8221; Moskowitz said. &#8220;I guess trying to avoid the obvious conclusion the inflection comes from the trial rollout.&#8221;
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26151642/Screenshot-2024-04-27-at-12.46.34%E2%80%AFAM-702x1024.png" alt="" class="wp-image-311493" /></figure>
Tesla&#8217;s FSD: A Risky Gamble?&nbsp;The&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38286437/tesla-ceo-elon-musk-says-going-balls-to-the-wall-for-autonomous-driving-is-blindingly-obvious-as-eve" rel="noreferrer noopener">success of FSD</a>&nbsp;is crucial for Tesla, as it forms the foundation of its planned&nbsp;robotaxi&nbsp;service. The company is scheduled to unveil its&nbsp;robotaxi&nbsp;program in August. However, concerns persist regarding the technology&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/news/23/10/35125361/exclusive-dawn-projects-dan-odowd-warns-teslas-terrible-fsd-could-be-banned-blames-musk-for-coordina" rel="noreferrer noopener">level of autonomy, safety</a>, and regulatory approval.
While some&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32357884/cathie-wood-unfazed-by-autopilot-concerns-calls-teslas-fsd-most-impactful-ai-projec" rel="noreferrer noopener">analysts believe FSD</a>&nbsp;could become a significant revenue driver for Tesla due to its recurring revenue model, they acknowledge it&#8217;s a long-term play. This adds pressure, especially with Tesla&#8217;s core electric vehicle business facing industry-wide challenges.
Tesla&#8217;s stock had been on a downward trend since the second half of 2023 but has shown some recovery since its first-quarter earnings announcement. The company&#8217;s confirmation of a low-cost model launch has offered investors a glimmer of hope.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38453144/teslas-robotaxi-plan-hasnt-excited-investors-but-fund-manager-gary-black-says-this-"> Tesla&#8217;s Robotaxi Plan Hasn&#8217;t Excited Investors, But Fund Manager Gary Black Says This Is What Matters More: &#8216;No Other Way To Interpret This&#8230;&#8217;</a>
Photo via Shutterstock

Rumors

Tesla 'Is Now Enron, Folks:' Facebook Co-Founder Claims Musk's EV Giant Is Cooking Up Some FSD Data

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has responded to the allegations of &#8220;consumer fraud on a massive scale&#8221; made by Facebook co-founder Dustin Moskovitz.
What Happened: On Thursday, Moskovitz, the CEO and co-founder of software company Asana, took to Threads and accused Tesla of fraudulent practices. He likened the EV giant&#8217;s actions to those of Enron, a corporation that <a href="https://www.benzinga.com/general/education/21/12/24405944/this-day-in-market-history-enron-declares-bankruptcy">went bankrupt in 2001</a> due to a massive accounting fraud.
&#8220;I know I sound crazy to most people who don&#8217;t follow $TSLA closely but at this point it really needs to be said. This is Enron now, folks,&#8221; he said, adding, &#8220;It may keep going, but people are going to jail at the end.&#8221;
He went on to say, &#8220;Tesla has committed consumer fraud on a massive scale, from lying about FSD, ranges, and (recently, unconfirmed!) even inflating odometers,&#8221; adding, &#8220;Many times now, also securities fraud.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/04/38349837/elon-musk-agrees-every-american-household-will-have-a-1-000-per-month-home-robot-in-7-years-time?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Agrees Every American Household Will Have A $1,000-Per-Month Home Robot In 7 Years&#8217; Time</a>
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26211753/Screenshot-2024-04-27-at-6.47.47%E2%80%AFAM-1024x788.png" alt="" class="wp-image-311685" /></figure>
Moskovitz&#8217;s allegations are based on&nbsp;a graph Tesla shared to&nbsp;mark a significant&nbsp;milestone: one billion miles driven&nbsp;using Full Self-Driving, the company&#8217;s&nbsp;advanced driver assist system. 
He&nbsp;said that Tesla is incorrectly recognizing its deferred revenue&nbsp;as earned revenue through the&nbsp;wider release of its Autopark&nbsp;feature, resulting in inflated numbers.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26211904/Screenshot-2024-04-27-at-6.48.56%E2%80%AFAM-1024x819.png" alt="" class="wp-image-311686" /></figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Musk has been responding to his allegations on X, formerly Twitter, mostly by ridiculing Moskovitz. In one of the posts on X, he said,&nbsp;&#8220;Yeah, Dustin is the one&nbsp;who should go to jail&nbsp;for impersonating a smart person,&#8221; Musk wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yeah, Dustin is the one who should go to jail for impersonating a smart person
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1783956942836379751?ref_src=twsrc%5Etfw">April 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: This is not the first time Moskovitz has criticized Tesla and Musk. Last year, he&nbsp;<a href="https://www.benzinga.com/23/11/35841525/elon-musk-under-fire-facebook-co-founder-calls-for-resignation-from-tesla-amid-antisemitism-controve">called for Musk&#8217;s resignation</a>&nbsp;from all his roles, including his position as CEO of Tesla, following a controversial tweet endorsing an antisemitic post. 
Moskovitz&#8217;s skepticism about Musk&#8217;s success also led to a <a href="https://www.benzinga.com/news/23/07/33453340/is-elon-musks-success-a-result-of-deception-facebook-co-founder-challenges-true-impact-of-tesla-spac">contentious debate</a> over whether Musk&#8217;s companies, Tesla and SpaceX, were as revolutionary as they were portrayed. 
&#8220;If they were really built on outward lies, rather than just self-deceptions (rose-colored glasses), then we should really see them as scams he got away with,&#8221; he said in July 2023. 
Meanwhile, Tesla has been facing a tumultuous period, with the company <a href="https://www.benzinga.com/news/earnings/24/04/38390883/tesla-q1-earnings-highlights-ev-giant-misses-wall-street-estimates-makes-cost-cuts-invests-in-ai-sp">reporting a 9% year-over-year revenue decrease</a> in the first quarter of 2024. The revenue total fell short of the Street consensus estimate of $22.15 billion, according to <a href="https://www.benzinga.com/pro/feature/newsfeed?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noreferrer noopener">data from Benzinga Pro.</a>
Price Action: Tesla shares closed 1.11% lower at $168.29 on Friday.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/04/38268298/when-elon-musk-met-jack-ma-and-instantly-regretted-it?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk's Tesla Slashes Price Of Full Self-Driving Package By Half: ‘…Now $99/Month'</a>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Elon Musk Claps Back At Facebook Co-Founder's Consumer Fraud Accusations Against Tesla: 'Should Go To Jail For Impersonating A Smart Person'

Netflix loves launching new stuff on its platform every week to keep things fresh but that also makes every weekend a bit of an adventure to try and stay ahead of what&#8217;s worth a watch and what&#8217;s just &#8216;meh.&#8217; Well, that&#8217;s where we step in.
With the sun shining, we&#8217;ve combed through all the new, new-to-us, and new-to-stream fare gracing the streamer's digital shelves to craft a watch list that spares you the trouble of wasting precious weekend hours in sifting through Netflix&#8217;s endless catalogue.
Here are our top picks for what to watch on Netflix this weekend:
<h3 class="wp-block-heading">1. Dead Boy Detectives</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103217/Dead-Boy-Detectives-1024x576.jpg" alt="Dead Boy Detectives is about a pair of teenagers investigating paranormal mysteries. Image credit: Tudum/ Netflix" class="wp-image-311009" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103217/Dead-Boy-Detectives-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103217/Dead-Boy-Detectives-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103217/Dead-Boy-Detectives-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103217/Dead-Boy-Detectives.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Dead Boy Detectives is about a pair of teenagers investigating paranormal mysteries. Image credit: Tudum/ Netflix</figcaption></figure>
Spawned from the imaginative world of Neil Gaiman's comics, Dead Boy Detectives tells the tale of two British teens who shun the afterlife to linger on Earth. Edwin and Charles, the spirited duo, along with Crystal, an American clairvoyant, journey to the U.S. to tackle eerie mysteries involving the supernatural. Their adventures are packed with encounters with ghosts, witches, and even Death itself as they roam the former colonies.
<h3 class="wp-block-heading">2. Anyone But You</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103425/Anyone-But-You-1024x576.jpg" alt="Anyone But You is an edgy comedy that features Sydney Sweeney and Glen Powell. Image credit: Tudum/ Netflix" class="wp-image-311016" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103425/Anyone-But-You-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103425/Anyone-But-You-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103425/Anyone-But-You-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103425/Anyone-But-You.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Anyone But You is an edgy comedy that features Sydney Sweeney and Glen Powell. Image credit: Tudum/ Netflix</figcaption></figure>
Turning a Shakespeare classic on its head, Anyone But You features a snappy, modern twist on &#8220;Much Ado About Nothing.&#8221; Sydney Sweeney and Glen Powell play Bea and Ben, who transform from hot to cold after a first date gone wrong, only to pretend to be an item at a frenzied wedding in Australia. This edgy comedy will have you guessing if they'll ever truly click.
<h3 class="wp-block-heading">3. Miller&#8217;s Girl</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103551/Millers-Girl-1024x576.jpeg" alt="Miller's Girl is headlined by Wednesday star Jenna Ortega and Martin Freeman. Image credit: Tudum/ Netflix" class="wp-image-311020" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103551/Millers-Girl-1024x576.jpeg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103551/Millers-Girl-300x169.jpeg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103551/Millers-Girl-768x432.jpeg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103551/Millers-Girl.jpeg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Miller&#8217;s Girl is headlined by Wednesday star Jenna Ortega and Martin Freeman. Image credit: Tudum/ Netflix</figcaption></figure>
In Miller&#8217;s Girl, Jenna Ortega and Martin Freeman dive into a narrative that blurs the lines between a mentorship and a tangled web of emotions. A young writer finds herself in deep waters as what begins as a creative pursuit with her professor spirals into a dark, manipulative relationship.
<h3 class="wp-block-heading">4. The Asunta Case</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103701/The-Asunta-Case-1024x576.jpg" alt="The Asunta Case is an investigative thriller starring Candela Peña and Tristán Ulloa. Image credit: Tudum/ Netflix" class="wp-image-311024" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103701/The-Asunta-Case-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103701/The-Asunta-Case-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103701/The-Asunta-Case-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103701/The-Asunta-Case.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">The Asunta Case is an investigative thriller starring Candela Peña and Tristán Ulloa. Image credit: Tudum/ Netflix</figcaption></figure>
The Asunta Case explores the chilling true story of Asunta Fong Yang, an adopted girl found murdered in Spain. The gripping series uncovers the layers of a high-profile case that shook the nation, questioning the very essence of parental love and betrayal. It's a must-watch for true crime aficionados.
<h3 class="wp-block-heading">5. King Richard</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103832/King-Richard-1024x576.jpg" alt="King Richard is a sports-biodrama about the father of Tennis superstars Venus and Serena Williams. Image credit: Tudum/ Netflix" class="wp-image-311027" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103832/King-Richard-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103832/King-Richard-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103832/King-Richard-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26103832/King-Richard.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">King Richard is a sports-bio-drama about the father of Tennis superstars Venus and Serena Williams. Image credit: Tudum/ Netflix</figcaption></figure>
Relive the inspiring story of Venus and Serena Williams through King Richard, a film that showcases their father's relentless coaching that led them to tennis stardom. This sports drama not only captured hearts but also won Will Smith an Oscar, making headlines for more reasons than one in 2022. Now streaming on Netflix for the first time, it's a perfect pick for sports enthusiasts and story lovers alike.
Netflix Photo by Burdun Iliya on Shutterstock

Entertainment

Can't Pick What To Watch? Here Are 5 New Netflix Releases Worth Your Weekend

In an exclusive&nbsp;interview, Christine Smith, founder and CEO of&nbsp;<a href="https://eatgron.com/">Gr&ouml;n Edibles</a>, provided an in-depth look at the economic dynamics of operating a cannabis edibles brand across various states.
2024 marks a significant year for Gr&ouml;n, with expansion into multiple U.S. markets including New York, New Jersey,<a href="https://www.benzinga.com/topic/ohio-cannabis"> Ohio</a>&nbsp;and <a href="https://www.benzinga.com/topic/maryland-cannabis">Maryland</a>, enhancing their presence to a total of eight U.S. and Canadian markets.
<h3>Strategic Expansion And Market Dynamics</h3>
Smith emphasized the strategic selection of states based on detailed market analysis. &quot;Each state is very different,&quot; <a href="https://www.benzinga.com/markets/cannabis/24/03/37945428/how-to-spot-and-seize-market-opportunities-with-products-you-love-top-cannabis-brand-founder-has">Smith</a> noted, highlighting the unique regulatory and market environments that influence their expansion strategy. For instance, Ohio&#39;s recent shift to adult use and its limited license model presents a promising market, similar to past <a href="https://www.benzinga.com/markets/cannabis/24/04/38078767/exclusive-missouris-cannabis-market-sees-surge-with-high-dose-products">successes in Missouri</a>.
While less structured, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36250035/a-2024-investor-guide-to-new-yorks-cannabis-market-expansion-the-mso-wealth-roadmap">New York offers vast potential</a> due to its focus on brand scalability. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33329222/the-maryland-effect-a-game-changer-for-the-east-coast-cannabis-industry">Maryland</a>, often overlooked, was chosen based on robust data analytics, including retailer and license counts, and market share opportunities, making it a strategic part of Gr&ouml;n&#39;s East Coast presence.
<h3>Supply Chain Complexity And Ingredient Sourcing: Adapting to Localized Manufacturing Needs</h3>
Gr&ouml;n&#39;s commitment to organic, single-origin ingredients and fair-trade certified suppliers, is a cornerstone of its market appeal, yet this approach presents considerable challenges in navigating the fragmented regulatory landscape of the U.S. cannabis market.
In states like Ohio, regulations prohibit the purchase of oil on the open market, necessitating that companies process oil only within the licensed facilities. To manage these challenges, Gr&ouml;n has diversified its sourcing strategy to ensure a steady supply of biomass, crucial for scalable operations as it enters new markets.
Smith noted the strategic importance of biomass availability: &quot;We will not enter a market if we don&#39;t know that we have the biomass and availability to be able to move at scale.&quot;
Further complicating their operations, Gr&ouml;n has adopted a unique manufacturing model to comply with varied state laws. &quot;We set up our kitchens in all of our facilities. We operate under a <a href="https://www.benzinga.com/markets/cannabis/23/11/35662129/are-traditional-cannabis-licensing-models-obsolete-how-reverse-licensing-can-help">reverse licensing model</a>,&quot; Smith described. In this model, Gr&ouml;n builds up a production space to their specifications under someone else&#39;s license, approved by the state.
This setup involves using their equipment, such as water-jacketed kettles for cooking gummies and tempering <a href="https://www.benzinga.com/markets/cannabis/23/02/31079080/if-you-like-chocolate-youll-love-gr-n-cannabis-edibles-made-by-an-architect-turned-confectioner">machines for chocolate</a>, making it &quot;much less of a kitchen and far more of a production manufacturing facility.&quot;
The need to tailor production processes to each state&#39;s regulations prevents the streamlining of operations across the board. In Canada, for instance, where Gr&ouml;n can operate nationally, the setup is significantly different and more efficient compared to the U.S., where they must establish separate facilities in each state.
&quot;The equipment we&#39;re using in Canada, which is national, allows us to do one facility for the entire country, is very different than what we&#39;re doing here in the States,&quot; Smith added, highlighting the extensive manual labor involved due to each state&#39;s distinct rules.
<h3>Technology And Operational Efficiency</h3>
For Gr&ouml;n, leveraging technology and innovative manufacturing processes is essential in <a href="https://www.benzinga.com/general/biotech/23/08/33579692/cannabis-robots-meet-the-company-boosting-efficiency-and-margins-through-packaging-automation">optimizing production costs</a> and ensuring <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">consistent product quality</a> across a wide range of markets.
Smith explained that this lack of uniformity leads to a reliance on both manual labor and automated systems, tailored to each location. Gr&ouml;n&rsquo;s operations require using smaller, more versatile equipment that can be adjusted to meet local requirements, thereby maintaining compliance while still striving for efficiency.
Moreover, Gr&ouml;n&#39;s approach to technology not only involves the physical machinery but also extends to their<a href="https://www.benzinga.com/general/biotech/23/02/30915385/exclusive-how-to-lower-the-cost-of-cannabis-quality-and-save-30-of-your-top-line-revenue"> software systems</a>, which must be flexible enough to handle varied regulatory demands from tracking and reporting to quality control.
<h3>Product Development And Consumer Engagement: Adapting to Local Markets</h3>
Gr&ouml;n&#39;s product development is deeply influenced by consumer trends, requiring a strategic balance between innovation and economic viability.
With over 250 SKUs tailored to meet the diverse regulatory and consumer landscapes of various states, Gr&ouml;n&#39;s approach to <a href="https://www.benzinga.com/news/23/04/32018716/exclusive-what-it-takes-to-build-a-successful-cannabis-edibles-brand-a-discussion-with-industry-lead">product creation and marketing</a> is meticulously localized.
Smith elaborates on the complexities involved in adapting product formulations to suit different markets, particularly when it comes to the use of <a href="https://www.benzinga.com/markets/cannabis/20/08/17023053/cannabis-concentrates-a-beginners-guide-1">cannabis extracts</a> like<a href="https://www.benzinga.com/markets/cannabis/24/03/37850817/vaping-emerges-as-a-preferred-method-for-rosin-consumption-in-cannabis-market"> rosin and distillate</a>.
&quot;We&#39;re using rosin depending on the market, and that&#39;s the thing because every market has a different availability as the markets mature,&quot; Smith explained. For example, in the West Coast markets like Oregon, there is a large and consistent availability of rosin, which allows for its broader use in products.
However, in other regions, the limited availability of such extracts requires Gr&ouml;n to adjust their formulations to include a blend of rosin and distillate based on what is locally accessible.
<h3>Pricing Across Markets</h3>
This variability in ingredient availability not only affects the type of products that can be offered in different states but also impacts Gr&ouml;n&#39;s pricing strategy. &quot;In Oregon, we can get oil for $1.50 a gram. On the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38282615/cannabis-brands-leading-market-expansion-in-east-midwest-a-look-at-prices-and-trend"> East Coast</a>, we&#39;re looking at oil for $15 a gram, sometimes $20 a gram,&quot; Smith noted, highlighting the significant cost differences that can affect product pricing and margins.
Despite these challenges, Gr&ouml;n is committed to maintaining a consistent quality and price point for consumers, which occasionally means absorbing higher costs in markets where inputs are more expensive.
The strategy involves a long-term view where initial sacrifices in margins are seen as an investment in establishing market presence and consumer trust. &quot;We sacrifice the margins on the front end for the longevity of having consistency and pricing,&quot; Smith added.
This approach is crucial for <a href="https://www.benzinga.com/news/24/03/37944162/is-the-future-of-the-marijuana-industry-shaped-by-consumer-packaged-goods-or-vice-versa">consumer packaged goods (CPG)</a> like those offered by Gr&ouml;n, where consumer expectations around product quality and price consistency are high.
Smith is optimistic about the future, focusing on minor cannabinoids and new product developments like low-dose sleep aids, reflecting Gr&ouml;n&#39;s commitment to innovation aligned with consumer needs.
&quot;We are 100% committed to <a href="https://www.benzinga.com/general/biotech/23/10/35300227/from-cbn-cbg-to-thcv-consumer-centric-brands-embrace-rare-cannabinoids-for-differentiation">minor cannabinoids</a>. They play a significant role in our product effects and formulations. Hopefully, we&#39;ll see clearer regulations from federal authorities soon,&rdquo; Smith said.
&ldquo;As for our investments in minor cannabinoids, we&#39;re <a href="https://www.benzinga.com/news/events/24/04/38185665/surge-in-missouris-cannabis-sales-spurs-new-product-launch-by-gr-n">doubling down</a>. We&#39;re excited about our upcoming product release in May&mdash;it&#39;s a super sleep aid featuring a 10 to 1 ratio, with 25mg of CBN and 2.5mg of THC. It&#39;s designed for consumers who prefer a lower dose than a full 10mg gummy. We&rsquo;re also exploring THC-V and sugar-free options, among other minor cannabinoids,&quot; Smith noted.
Photo: AI-Generated Image.&nbsp;

Cannabis

Government

Regulations

Emerging Markets

Entrepreneurship

Retail Sales

Management

Success Stories

Exclusives

Interview

Inside Grön's Marijuana Edibles Factory: What Can We Learn About Choco-Nomics And Multi-State Expansion?

<h3 class="wp-block-heading">Congresswoman Advocates for Marijuana Banking Reform</h3>
In a bid to advance cannabis legislation, Congresswoman Maxine Waters (D- CA) champions the need for marijuana<a href="https://www.benzinga.com/markets/cannabis/24/04/38416745/three-pathways-to-federal-cannabis-legalization-that-investors-are-watching-closely"> banking reform,</a> highlighting bipartisan collaboration. Waters, a ranking member of the House Financial Services Committee, stresses the urgency of passing the <a href="https://www.benzinga.com/topic/safe-banking-act">Secure and Fair Enforcement Regulation </a>(SAFER) Banking Act, <a href="https://www.marijuanamoment.net/key-congresswoman-says-now-is-the-time-to-pass-marijuana-banking-bill-despite-mcconnells-concerns/">reported </a>Marijuana Moment. This legislation aims to provide banking services to cannabis businesses, addressing their current lack of access to traditional financial institutions due to federal prohibition.
Despite potential challenges from Senate Minority Leader Mitch McConnell, Waters expresses optimism and determination to overcome obstacles. 
"I know that there may be some concerns with McConnell, but I am hopeful that we can overcome that (&#8230;), we've got to have SAFER Banking, and most of us who have been working on this support that." 
<h3 class="wp-block-heading">Washington State Proposes Diversity Measures For Cannabis Ownership</h3>
The <a href="https://www.benzinga.com/markets/cannabis/23/02/30902464/washington-state-liquor-and-cannabis-officials-face-obstacles-to-personal-use-under-federal-laws">Washington State Liquor and Cannabis Board (WSLCB)</a> introduces amendments to foster diversity in cannabis ownership. With a focus on inclusivity, the proposed changes aim to encourage minority participation and eliminate licensing barriers in cannabis retail. Acknowledging the importance of equitable access, the WSLCB seeks to create a more inclusive landscape.
The WSLCB members<a href="https://tvw.org/video/washington-state-liquor-and-cannabis-board-2024041034/?eventID=2024041034"> received a briefing</a> on proposed changes to the scoring criteria for minority license applicants, aiming to prioritize those most affected by the war on drugs. One proposed change involves considering convictions for all drugs, not just marijuana, in the scoring process. These revisions to the scoring system reflect feedback from social equity applicants in the initial round of applications.
<h3 class="wp-block-heading">New Hampshire Senate Reviews Marijuana Legalization Bill</h3>
A New Hampshire bill legalizing marijuana, passed by the House, now faces scrutiny in a Senate committee. Opponents, including state Sen. Daryl Abbas (R) and Senate president Jeb Bradley (R), propose significant modifications.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Senate Judiciary (04/25/2024)" width="500" height="281" src="https://www.youtube.com/embed/qQHRZsEvhcQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<figcaption class="wp-element-caption">Senate Judiciary Session of 04/25/2024</figcaption></figure>
Earlier this year, the House-approved <a href="https://legiscan.com/NH/bill/HB1633/2024">HB 1633</a> permits 15 statewide retail stores, imposing a 10% state charge on adult-use purchases. Medical marijuana remains tax-exempt and regulated under an &#8220;agency store&#8221; model with strict marketing limitations.
Abbas&#8217;s proposed changes aim to elevate penalties for<a href="https://www.benzinga.com/markets/cannabis/24/04/38326268/cannabis-consumption-legal-or-not-in-your-state-everyone-seems-to-be-consuming-at-equal-rates-ne"> public consumption</a>, turning repeat offenses into misdemeanors with potential jail time, contradicting legalization goals. Additionally, Abbas&#8217;s amendment suggests a shift to a franchise system, overseen by the state&#8217;s Liquor Commission, governing the aesthetics and operations of the 15 stores. This, among other amendments, might distort the original spirit of HB1633, putting it at risk of failing in the House when revised, proponents of the bill alerted.

Push For Cannabis Banking Reform, Washington Social Equity, New Hampshire Debates Retail Weed Sales And More

With the potential legalization of adult-use marijuana under Amendment 3, Florida&#39;s cannabis market is set for a significant transformation. <a href="https://www.benzinga.com/topic/florida-cannabis">Florida&#39;s legal cannabis</a> spending is projected to grow at a 12% CAGR from 2023 to 2028, with total sales expected to reach $4.5 billion by 2028, positioning Florida as the second-largest U.S. cannabis market after California.
<h3>Competitive Landscape And Consumer Behavior</h3>
Florida&#39;s retail cannabis landscape has already shown significant growth, with the number of dispensaries rising to 628 by April 2024, as per&nbsp;<a href="https://www.benzinga.com/topic/bdsa">BDSA</a> data.&nbsp;
The state&#39;s medical cannabis sector remains robust, with patient numbers surpassing 878,000 this month and sales reaching $2.6 billion in 2023, marking an 18% increase from the previous year.
As Florida prepares for a November ballot initiative on adult-use legalization, BDSA analyst Brendan Mitchel-Chesebro underscores the legislative uncertainty around <a href="https://www.benzinga.com/markets/cannabis/24/04/38299011/its-on-the-ballot-the-future-of-adult-use-cannabis-in-florida-whats-the-contingency-plan-if-lega">Amendment 3</a>, which allows but does not require the expansion of adult-use cannabis licenses.
This leaves the future market landscape uncertain. If the initiative passes, BDSA forecasts sales of $874 million in 2025 for the adult-use segment.
In this context, existing operators like <a href="https://www.benzinga.com/markets/cannabis/24/04/38313915/cannabis-in-florida-the-bellamy-brothers-tell-trulieve-ceo-we-rolled-a-fat-one-when-legalization">Trulieve</a> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tcnnf#OTC">TCNNF</a>) are advised to refine their strategies to cater to a potentially larger and more diverse consumer base.
As consumer penetration rates are expected to surge&mdash;mirroring trends observed in other states transitioning to adult use&mdash;companies must adeptly navigate evolving preferences across different product forms and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37666783/marijuana-shoppers-favorite-strains-2024">usage motivations</a> to maintain or enhance their market shares.
Mitchel-Chesebro points out that, unlike other adult-use markets, only 31% of Florida consumers currently prioritize <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38341510/how-to-max-profits-this-420-smart-discounts-amid-sales-spike-of-premium-marijuana">low-cost</a>, compared to 36% in general adult-use markets.
However, the typical initial price increase following legalization might heighten price sensitivity among <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin">Florida shoppers</a>.
This, along with the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36268367/u-s-cannabis-market-premium-products">growing popularity of infused pre-rolls</a> and a notable 47% year-over-year growth in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33369455/sweet-treats-take-over-gummie-consumption-outpaces-flower-in-latest-consumer-data-h">edibles sales</a>, indicates significant upcoming shifts in consumer behavior as the market expands.
<h3>Strategies For Market Entry And Expansion</h3>
As the Florida market braces for a likely uptick in mergers and acquisitions, Mitchel-Chesebro advises new entrants and expanding firms to adopt a nuanced pricing strategy.
Using BDSA&rsquo;s Price Tiers analysis, he highlights the potential for brands to capitalize on specific product segments where premium offerings are underrepresented relative to their market performance.
For example, in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35991290/analyst-inside-look-trends-and-opportunities-in-ohios-emerging-recreational-cannabi">markets like Ohio</a>, premium-priced flower products disproportionately contribute to sales relative to their market availability. Identifying and targeting these lucrative price tiers can be a key strategy for newly introduced brands aiming for rapid growth in new markets.
Photo: AI-Generated Image.&nbsp;

Analyst Color

TCNNF

Landing In Florida's Cannabis Market: Legal Adult-Use Marijuana Could Yield $874M In 2025

<h3 class="wp-block-heading">Health Recall: Microbial Contamination Alert In British Columbia</h3>
In an uncommon event, <a href="https://recalls-rappels.canada.ca/en/alert-recall/sirona-pharma-inc-acreage-pharms-ltd-recalls-one-lot-full-sesh-purple-gelato-punch">Health Canada </a><a href="https://recalls-rappels.canada.ca/en/alert-recall/sirona-pharma-inc-acreage-pharms-ltd-recalls-one-lot-full-sesh-purple-gelato-punch">recalls Sirona Pharma Inc.&#8217;s Full Sesh Purple Gelato Punch</a> dried cannabis sold in British Columbia due to microbial contamination. The recall responds to a quality control measure.
<a href="https://www.benzinga.com/markets/cannabis/23/09/34548455/medical-cannabis-in-canada-faces-decline-whats-behind-the-38-drop-in-registrations">Health Canada&#8217;s </a>Cannabis Data Gathering Program identified microbial contaminant levels exceeding specified limits, potentially posing health risks. While no adverse health reports have been received, consumers have been alerted and are advised to cease using the recalled product immediately. With 1200 units sold between September 18, 2023, and April 18, 2024, the product must be returned to retailers or disposed of safely. Further specification on the contaminant was not made public. 
<h3 class="wp-block-heading">Manitoba&#8217;s Home Cultivation Ban Reversal: Shifting Regulations</h3>
Manitoba&#8217;s political landscape is undergoing a significant shift as the <a href="https://winnipeg.citynews.ca/2024/04/19/manitoba-set-to-remove-provinces-ban-on-growing-cannabis/">provincial government plans to overturn its ban on homegrown cannabis cultivation</a>. Aligned with federal law and evolving societal attitudes, this reversal reflects changing political dynamics and public sentiment regarding cannabis regulations.
The decision comes as Manitoba and Quebec were the only provinces to enforce restrictions against growing adult-use marijuana at home following <a href="https://www.benzinga.com/topic/canada-cannabis">Canada&#8217;s </a>legalization of recreational cannabis in 2018. With the New Democratic Party of Manitoba (NDP) now in power, the province anticipates lifting the ban, marking a pivotal moment in cannabis policy reform.
<h3 class="wp-block-heading">International Expansion: Greenway Greenhouse Cannabis Corporation Receives Certifications</h3>
In other news, <a href="https://www.benzinga.com/markets/cannabis/23/09/34951623/greenway-greenhouse-cannabis-launches-first-brands-in-the-canadian-market">Greenway Greenhouse</a> Cannabis Corporation (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GWAY#CSE">GWAY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GWAYF#OTCQB">GWAYF</a>) <a href="https://www.prnewswire.com/news-releases/greenway-receives-international-cannabis-accreditation-302128092.html">announced </a>a significant milestone as its cultivation facility in Leamington, Ontario receives CUMS-GAP and GACP certification. This achievement positions Greenway to distribute its high-quality greenhouse cannabis internationally, tapping into new markets and revenue streams.
The certifications, completed through Control Union, demonstrate compliance with strict international standards, allowing Greenway to engage with multiple international cannabis purchasers. With an annual cultivation capacity of 24,000 kg, Greenway aims to capitalize on the export market&#8217;s potential, enhancing revenue, gross margins, and global presence.
&#8220;Receiving these certifications opens up a whole new world of opportunities for Greenway,&#8221; said Jamie D&#8217;Alimonte, CEO of Greenway. &#8220;With our most recent expansion, we are able to scale up production to meet any new demand for our product internationally.&#8221;
As Canada&#8217;s cannabis industry continues to evolve, these developments signal both challenges and opportunities for stakeholders, shaping the future of cannabis regulation, consumer safety and market expansion.

Media

CSE:GWAY

GWAYF

Canada Cannabis Update: Health Recall, Home Cultivation Ban Reversal, International Expansion

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 5 years by 5.0% on an annualized basis producing an average annual return of 16.57%. Currently, IDEXX Laboratories has a market capitalization of $41.47 billion. 
Buying $1000 In IDXX: If an investor had bought $1000 of IDXX stock 5 years ago, it would be worth $2,164.47 today based on a price of $499.30 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714167027_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IDXX

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 10 years by 13.17% on an annualized basis producing an average annual return of 23.61%. Currently, Progressive has a market capitalization of $121.84 billion. 
Buying $1000 In PGR: If an investor had bought $1000 of PGR stock 10 years ago, it would be worth $8,578.56 today based on a price of $208.03 for PGR at the time of writing.
<h3>Progressive's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714167022_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth $8,600 Today

During the last three months, 4 analysts shared their evaluations of Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bread Finl Hldgs, presenting an average target of $34.75, a high estimate of $48.00, and a low estimate of $26.00. Surpassing the previous average price target of $30.33, the current average has increased by 14.57%.
<img src="https://www.benzinga.com/files/images/story/2024/1714165300_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bread Finl Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Bill Carcache</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bread Finl Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bread Finl Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bread Finl Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bread Finl Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BFH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bread Finl Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Bread Finl Hldgs</h2>
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains minority interest in its recently spun-off LoyaltyOne division, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
<h3>Financial Milestones: Bread Finl Hldgs's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Bread Finl Hldgs's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -1.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Bread Finl Hldgs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bread Finl Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.49%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bread Finl Hldgs's debt-to-equity ratio is below the industry average at 1.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Bread Finl Hldgs

In the preceding three months, 4 analysts have released ratings for Reliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $360.5, a high estimate of $380.00, and a low estimate of $345.00. This upward trend is apparent, with the current average reflecting a 17.24% increase from the previous average price target of $307.50.
<img src="https://www.benzinga.com/files/images/story/2024/1714165265_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Reliance. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Daniel Knauff</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$362.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reliance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Reliance compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Reliance's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Reliance analyst ratings.</a>
<h2>About Reliance</h2>
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
<h3>Understanding the Numbers: Reliance's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Reliance's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -7.57% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Reliance's net margin excels beyond industry benchmarks, reaching 8.17%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Reliance's ROE excels beyond industry benchmarks, reaching 3.53%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Reliance's ROA excels beyond industry benchmarks, reaching 2.6%. This signifies efficient management of assets and strong financial health.
Debt Management: Reliance's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For Reliance

Analysts' ratings for VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated VF and provided 12-month price targets. The average target is $16.38, accompanied by a high estimate of $22.00 and a low estimate of $12.00. A 9.25% drop is evident in the current average compared to the previous average price target of $18.05. 
<img src="https://www.benzinga.com/files/images/story/2024/1714165258_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive VF. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laurent Vasilescu</td>
<td>Exane BNP Paribas</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.50</td>
<td>$15.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to VF. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of VF compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of VF's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of VF's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VFC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on VF analyst ratings.</a>
<h2>Get to Know VF Better</h2>
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
<h3>Unraveling the Financial Story of VF</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: VF's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -16.16%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: VF's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): VF's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.97%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): VF's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.33%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: VF's debt-to-equity ratio stands notably higher than the industry average, reaching 3.48. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Assess VF: What You Need To Know

Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) has outperformed the market over the past 15 years by 3.58% on an annualized basis producing an average annual return of 15.74%. Currently, Eagle Materials has a market capitalization of $8.84 billion. 
Buying $100 In EXP: If an investor had bought $100 of EXP stock 15 years ago, it would be worth $921.72 today based on a price of $256.70 for EXP at the time of writing.
<h3>Eagle Materials's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714165230_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $900 Today

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Staar Surgical (STAA – Research Report), Krystal B...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Krystal Biotech (KRYS) and Bristol-Myers Squibb (BMY)

Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch

Krystal Biotech Inc (KRYS) is near the top in its industry group according to InvestorsObserver. KRYS gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Krystal Biotech Inc gets a 71 rank in the Biotechnology industry. Biotechnology is number 15 out of 148 industries. KRYS has an Overall S

Should You Accumulate Krystal Biotech Inc (KRYS) in Biotechnology Industry?

A rating of 75 puts Krystal Biotech Inc (KRYS) near the top of the Healthcare sector according to InvestorsObserver.Krystal Biotech Inc's score of 75 means that it ranks higher than 75% of stocks in the sector. In addition, its overall score of 84 ranks it higher than 84% of all stocks. KRYS has an Overall Score of 84. Fin

Will Krystal Biotech Inc (KRYS) Outperform the Rest of the Stocks in the Healthcare Sector?

Krystal Biotech confirms cancellation from Cowen conference due to CEO sickness

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

Krystal Biotech Inc (KRYS) is near the top in its industry group according to InvestorsObserver. KRYS gets an overall rating of 63. That means it scores higher than 63 percent of stocks. Krystal Biotech Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries. KRYS has an Overall S

Should Biotechnology Stock Krystal Biotech Inc (KRYS) Be in Your Portfolio Tuesday?

A rating of 83 puts Krystal Biotech Inc (KRYS) near the top of the Healthcare sector according to InvestorsObserver.Krystal Biotech Inc's score of 83 means that it ranks higher than 83% of stocks in the sector. In addition, its overall score of 88 ranks it higher than 88% of all stocks. KRYS has an Overall Score of 88. Fin

Will Krystal Biotech Inc (KRYS) Stay at the Top of the Healthcare Sector?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them. These three strong buy <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are joining the upper ranks of their industry with promising new drugs and encouraging financials that justify serious consideration. 



Given the timeline of clinical trials and new releases, these biotech stocks can be some of the best buy-and-hold stocks.&nbsp;



Let&rsquo;s see why investors should add these strong buy biotech stocks to their Q2 watchlist for some promising returns and potential record-setting quarterly numbers this year.



<h2>Axsome Therapeutics (AXSM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/axsm-stock-300x169.jpg" alt="A magnifying glass zooms in on the Axsome Therapeutics, Inc. (AXSM) logo"><div>Source: Pavel Kapysh/Shutterstock.com</div></div>Axsome Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/axsm-stock-quote/">AXSM</a>) is a leading producer of treatments for common conditions such as depression, narcolepsy and migraines. Over the last few years, Axsome has had clinical breakthroughs, with the approval of its depression treatment, Auvelity. In addition, Axsome acquired the narcolepsy treatment Sunosi from Jazz Pharmaceuticals in 2022.&nbsp;



Thanks to Auvelity and Sunosi, Axsome saw substantial product <a href="https://axsometherapeuticsinc.gcs-web.com/node/11251/pdf">revenue growth</a> from 2022 to 2023, reaching a 309% year-over-year growth rate. Total revenue also increased five times as much, with Auvelity accounting for $130.1 million and Sunosi $74.8 million of that total.



Axsome is also continuing clinical studies to expand the application of these two drugs to treat <a href="https://www.axsome.com/publications/AAN_2023_SHARP_Study_Topline_040623.pdf">sleep</a> and eating disorders. The company hopes to add more bestsellers, such as <a href="https://www.axsome.com/publications/SLEEP-Poster_2020-Final.pdf">AXS-12</a> to treat narcolepsy and <a href="https://www.axsome.com/publications/AHS_2021_MOVEMENT_poster_4_30_21_FINAL.pdf">AXS-07</a> to treat migraines.



With Axsome&rsquo;s current momentum and the announcement of results from its ongoing trials, this stock is a must for your watchlist this year.



<h2>Krystal Biotech (KRYS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>Known for its drug Vyjuvek, a dystrophic epidermolysis bullosa (DEB) treatment, Krystal Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/krys-stock-quote/">KRYS</a>) has risen to the top of the biotech ranks since last year. Following its FDA approval in May last year, Vyjuvek generated <a href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2023">$50.7</a> million in product revenue for Krystal in 2023.



More than $40 million of that product revenue was generated in <a href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2023">Q4</a> alone, making that number even more impressive. You can probably guess, but this report exceeded expectations and earned Krystal its current position in the market.



Spreading its reach into <a href="https://ir.krystalbio.com/static-files/cee89ff1-0c7a-453e-b283-fed2b829f652">treatments</a> for respiratory conditions, Krystal is currently in phase 1-2 clinical trials for cystic fibrosis (KB407) and alpha-a antitrypsin deficiency (KB408). Other trials include oncology, dermatology and ophthalmology treatments.&nbsp;



Krystal Biotech is another company surging to the top of biotech with record sales and excellent prospects for continued growth this year.



<h2>Catalyst Pharmaceuticals (CPRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/cprx-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website of Catalyst Pharmaceuticals (CPRX)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Catalyst Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cprx-stock-quote/">CPRX</a>) has had ups and downs since last year but has managed to find its way to the top ranks of biotech time and time again. After coming off of an immaculate Q4 with an 82% increase in <a href="https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-reports-strong-fourth-quarter-and-full">revenue</a> and a year-over-year jump of 85.9% in yearly revenue.&nbsp;



Not to mention an earnings beat, with adjusted EPS of $0.63. How did they do it? The answer is the company&rsquo;s two hot-selling products, Fycompa and Firdapse. Fycompa is an anti-seizure medication and Firapse is used to treat Lambert-Eaton myasthenic syndrome (LEMS), an autoimmune condition common in lung cancer patients. Both treatments had record sales in 2023, generating $396.5 million in combined product revenue. With current momentum, there is no better time to give Catalyst the attention it is due as a top pick for biotech stocks this year.



On the date of publication, Joel Lim did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Joel Lim is a finance freelance writer who writes content for several companies like LTSE and Realtor, along with financial publications, including Mises Institute and Foundation for Economic Education.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/3-strong-buy-biotech-stocks-to-add-to-your-q2-must-watch-list/">3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...

Wall Street Analysts Are Bullish on Top Healthcare Picks

AXSM

CPRX

KRRO

MREO

RARE

STAA

TKPHF

Press Releases

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Health Care

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Krystal Biotech to Report Fourth Quarter and Full Year 2023  Financial Results on February 26, 2024

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Opinion

Thinking about buying stock in GameStop, Equinix, Lyra Therapeutics, Krystal Biotech, or KULR Technology?

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung